Diabetes Metab J.  2024 Nov;48(6):1176-1178. 10.4093/dmj.2024.0551.

Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29)

• Lee J
• Moon JH

• KMID: 2561801
• DOI: http://doi.org/10.4093/dmj.2024.0551

Reference

1. Fan Y, Yan Z, Li T, Li A, Fan X, Qi Z, et al. Primordial drivers of diabetes heart disease: comprehensive insights into insulin resistance. Diabetes Metab J. 2024; 48:19–36.

2. Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, et al. Heart failure in diabetes. Metabolism. 2021; 125:154910.

3. Cho DH, Park SM. Epicardial adipose tissue and heart failure, friend or foe? Diabetes Metab J. 2024; 48:373–84.

4. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381:1995–2008.

5. Li SS, Pan L, Zhang ZY, Zhou MD, Chen XF, Qian LL, et al. Diabetes promotes myocardial fibrosis via AMPK/EZH2/PPAR-γ signaling pathway. Diabetes Metab J. 2024; 48:716–29.

6. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013; 6:395–402.

7. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res. 2010; 87:504–13.

8. Wei WY, Zhang N, Li LL, Ma ZG, Xu M, Yuan YP, et al. Pioglitazone alleviates cardiac fibrosis and inhibits endothelial to mesenchymal transition induced by pressure overload. Cell Physiol Biochem. 2018; 45:26–36.

9. Elrashidy RA, Asker ME, Mohamed HE. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012; 17:324–33.

10. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011; 342:d1309.

11. Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024; 627:221–8.